Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
Panelists discuss how treatment approaches differ between platinum-sensitive and platinum-resistant ovarian cancer patients, emphasizing the use of platinum doublets and maintenance therapies in sensitive cases versus the limited options historically available for resistant cases.
Evolving Ovarian Cancer Treatment Landscape
The treatment landscape for recurrent platinum-resistant ovarian cancer has significantly evolved. Historically, options like doxil and gemcitabine offered limited efficacy, often resulting in minimal patient benefit. The discussion highlights how antibody-drug conjugates (ADCs) have emerged as promising new therapies, especially for those who have exhausted traditional platinum-based regimens.
For platinum-sensitive cases, reusing platinum doublets based on treatment-free intervals remains common. Selection between doublets like platinum-taxane, platinum-doxil, or platinum-gemcitabine depends on factors such as toxicity, patient lifestyle, and clinical trial eligibility. Strategic planning even from first-line treatment can influence second-line trial participation.
Maintenance therapies, including PARP inhibitors and bevacizumab, are critical in prolonging disease control. However, regulatory changes have restricted the use of PARP inhibitors in biomarker-negative cases. As ADCs targeting folate receptor alpha become more prevalent, they could potentially reshape maintenance strategies in the platinum-sensitive setting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
